Hays published the Global Big Pharma H1 2026 Revenue Ranking for 2026.
Public source
Publisher name
Public post
••• Global Big Pharma - H1 2026 Revenue Ranking ••• For more follow #TuesdaysLifeSciencesRanking • Johnson & Johnson ($49.40B): Retains the #1 spot globally through posi…
Company
Hays
Working for your tomorrow
- Industry
- Staffing and Recruiting
- Location
- London, GB
- Company size
- 10,001+ employees
About Hays
At Hays, we believe that the right job can transform a person's life - and the right person can transform a business. From career‑defining opportunities to complex workforce strategies, we connect ambition with opportunity - helping people and organisations reimagine what’s possible. Every year we place over 200,000 professionals into new roles. Whether it’s a permanent role or a temporary contract, our specialist consultants provide tailored advice and market intelligence to accelerate careers, from emerging talent to executive leadership. For organisations, our expert teams build recruitment and workforce solutions shaped by real-time market insights, local expertise and the scale of a world leading specialist in white collar hiring. With operations in 30 countries, over 200 offices and 9,500 colleagues worldwide, we fill around 1,000 roles every working day. The future of work isn’t something we’re waiting for. We’re creating it every day.
See moreLatest activity
Latest activity from Hays
174 signals
People
Hays is hiring a full-time on-site Project Manager for the beheer of multiple telecom infrastructure projects in Mechelen starting in October 2026.
People
Hays is looking for a project manager with at least 3 years of experience in project management, telecom, infrastructure, or construction projects.
People
Hays is looking for a senior project leader for infrastructure deployment in Mechelen on-site with Nederlands and English requirements.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Retrained Search
Retrained Search noted that Hays experienced FY26 net fees down 8% to £905.5m with profit only moving up because they cut £50m of cost out of the business.
Capital & Finance
CY Partners
CY Partners reports that average clinical trial setup times for the UK life sciences sector dropped from 169 days to 122 days in the first half of 2025/2026.
Capital & Finance
Randstad USA
Randstad USA observed a recent influx of massive Series A and B rounds, highlighted by breakthroughs from Typewriter Therapeutics, Big Hat Biosciences, and Super Luminal.
Capital & Finance
Vector Talent
Vector Talent notes that Samsung Biologics is raising $2.18B, with $1.97B allocated to the PolyPeptide Group acquisition and $210M allocated to Bio Campus II.
Capital & Finance
Reed